JAMES HALL: Open Payments
NPI 1295735504 · KANSAS CITY, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$640 in 33 payments from 15 companies in 2025. Trend: 2023 $1,258 · 2024 $1,566 · 2025 $640
Food & beverage: $640
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 6 | $147 |
| ABBVIE INC. | 4 | $74 |
| Lilly USA, LLC | 4 | $73 |
| Abbott Laboratories | 3 | $68 |
| Astellas Pharma US Inc | 3 | $63 |
| Amgen Inc. | 2 | $33 |
| E.R. Squibb & Sons, L.L.C. | 2 | $30 |
| Novo Nordisk Inc | 2 | $29 |
| Eisai Inc. | 1 | $21 |
| IBSA Pharma Inc. | 1 | $19 |
Products named: BREZTRI, FREESTYLE LIBRE 3, Veozah, VRAYLAR, MOUNJARO, ZEPBOUND, UBRELVY, OTEZLA.
Industry payments across MO — which companies pay providers there.
